BioCentury
ARTICLE | Clinical News

Baminercept: Interim Phase IIa data

November 12, 2007 8:00 AM UTC

Interim data from a double-blind, placebo-controlled, dose-escalation Phase IIa trial in 30 evaluable patients showed that subcutaneous baminercept plus methotrexate (MTX) improved ACR measures vs. MT...